B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NAPRT

MOLECULAR TARGET

nicotinate phosphoribosyltransferase

UniProt: Q6XQN6NCBI Gene: 9310011 compounds

NAPRT (nicotinate phosphoribosyltransferase) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NAPRT

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1flufenamic acid4.1462
2benzoic acid4.1160
3mefenamic acid3.9350
42 picolinic acid2.8316
5Salicylic Acid1.102
6Aminopyrine0.691
7Antipyrine0.691
8Oxyphenbutazone0.691
9Phenylbutazone0.691
10Picloram0.691
11Sulfinpyrazone0.691

About NAPRT as a Drug Target

NAPRT (nicotinate phosphoribosyltransferase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented NAPRT interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NAPRT inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.